Gilead Sciences reported $27.3 billion in year-end revenue for 2021, anchored by sales of its COVID-19 therapeutic remdesivir, known by the brand name Veklury.
Read the full post on Becker's Hospital Review - Healthcare News
Gilead saw $5.6B in remdesivir sales last year
